CompletedNot Applicable

Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)

Spain503 participantsStarted 2012-12-17

Plain-language summary

Post-authorisation observational study to assess the evolution in normal clinical practice of patients recently diagnosed with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukaemia (CMML), depending on the moment when active treatment is initiated. Subjects will be recruited from approximately 50 haematology sites in Spain.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓1. Male or female subjects, aged 18 years or older. 2. Subjects with documented diagose of MDS or CMML within the last 3 months prior to entering the study and naive to treatment.

What they're measuring

Event Free Survival

Timeframe: Up to a minimum of 36 months' follow-up from the start of active treatment

Trial details

NCT IDNCT02085798

SponsorCelgene

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2015-08-31

View on ClinicalTrials.gov More Myelodysplastic Syndrome trials